CriticalAntiretroviral, HIV protease inhibitor×Prokinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)
Updated · Methodology
Mechanism
The liver metabolises atazanavir through CYP3A4, and atazanavir itself inhibits this enzyme, so levels of drugs cleared by the same pathway can rise (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). The atazanavir SmPC lists cisapride among CYP3A4 substrates with a narrow therapeutic margin. The boosters inhibit this enzyme even more: ritonavir is a stronger CYP3A4 inhibitor than atazanavir, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). The documents give no study data with figures for this pair. According to the ritonavir SmPC, higher cisapride levels raise the risk of serious arrhythmias. The SmPC of clarithromycin, another CYP3A4 inhibitor, states that high cisapride levels can prolong the QT interval and cause ventricular arrhythmias (ritonavir SmPC, EMA; clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
The danger of this combination is serious heart rhythm disorders (atazanavir label, US Food and Drug Administration, FDA): QT prolongation, ventricular tachycardia, ventricular fibrillation and torsade de pointes (clarithromycin summary of product characteristics on its combination with cisapride, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes sudden palpitations, dizziness or fainting. In some people atazanavir prolongs the PR interval: atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir FDA label).
Management
The combination is contraindicated. Cisapride is named in the contraindications of atazanavir with or without ritonavir and of atazanavir/cobicistat (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). With ritonavir, the ritonavir SmPC also contraindicates cisapride (ritonavir SmPC, EMA). The atazanavir SmPC asks prescribers to refer to the ritonavir SmPC before starting atazanavir with ritonavir (atazanavir SmPC, EMA). Cisapride is not in the Spanish medicines register CIMA, so the level of risk comes from the atazanavir and ritonavir documents. If a patient takes cisapride obtained in another country, do not prescribe atazanavir with it (atazanavir SmPC, EMA). Take special precautions when atazanavir is given with drugs that may prolong the QT interval or to people with bradycardia, congenital QT prolongation or electrolyte imbalance. In people with pre-existing second-degree or higher atrioventricular block or bundle branch block, use atazanavir with caution and only if the benefit outweighs the risk (atazanavir SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Claritromicina, Klacid 500 mg (nº registro 60515) (2024)– AEMPS, CIMA, nº registro 60515 (Klacid 500 mg comprimidos recubiertos con película), revisión 10/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5